Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue Medical/Specialty Pharmacy Prior Auth…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFlorida BluePolicy N/A

    Medical/Specialty Pharmacy Drugs Requiring Prior Authorization

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Florida Blue prior authorization requirements, submission routing, and product-specific handling for medical benefit–processed specialty (Rx) drugs and identifies drugs/HCPCS/CPT codes listed for prior auth review.

    Policy Summary
    PayerFlorida Blue
    PolicyMedical/Specialty Pharmacy Drugs Requiring Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2025
    Last ReviewApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to the vendor identified by Place of Service, Rendering Entity Participation Status, Specific Drug, and Member Product Type (e.g., Prime Therapeutics, Caremark/OptumRx, CareCentrix, Availity/Blue Express).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+drug entries listed in this segment
    ~120J-code/drug entries shown
    Q5143/Q5140/J3392new HCPCS/Q codes ref (01/01/2025)
    C9399dominant HCPCS placeholder
    multipleSAD/PADP flags present

    Coverage criteria and listing

    Member's products and coverage vary based upon the policy type and benefits. All services must meet the definition of medical necessity as outlined in the Member's benefit contract. Select benefit types enforce prior authorization to ensure the services align with the medical necessity criteria before the services are rendered, while other benefits verify the medical necessity criteria through post-service or concurrent review.

    For products that require a prior authorization, failure to obtain an authorization prior to the service being rendered may result in the services (and supportive services) being denied which may apply financial liability to the member and/or provider depending upon contract arrangements.

    Below are the standard product types that require a prior authorization for the Medical/Specialty Pharmacy (Rx) Drugs:

    - BlueCare HMO

    - My Blue*

    - Medicare Advantage HMO*

    - BlueOptions ACA Plans (Group & Individual plans)

    - BlueChoice Group ACA Plans (effective 4/1/2016)

    - Medicare Advantage PPO

    - SimplyBlue Group

    - Prior Authorization required in addition to referral when applicable

    NOTE: Products that do not require authorization for the listed drugs are eligible for a Voluntary Predetermination of Select Services.

    The Medical/Specialty Pharmacy (Rx) Drug List does NOT identify the following:

    - Medical Specialty Pharmacy (Rx) Drugs listed do NOT guarantee coverage is available through the member's medical benefit. Eligibility and benefits (E&B) must be verified prior to providing services.

    - The list does NOT identify prior authorization requirements for drugs processed and covered through the member's Pharmacy Benefit.

    - The list should NOT be used as reference for BlueCard out-of-area members. Contact BlueCard Eligibility for out-of-area eligibility and coverage.

    The HCPCS/CPT drug listing below is a catalog mapping HCPCS/J-codes to drug names, generic alternatives, internal flags (PADP, CEI, SAD) and relevant dates. Entries may indicate special handling such as “Drug not separately allowed, bundled within.” Presence on this list does NOT by itself indicate coverage; benefits vary by plan and prior authorization may still be required.

    Representative entries (not exhaustive):

    - C9399 — TYMLOS (ABALOPARATIDE) — SAD**L 08/02/2019

    - C9399 — UKONIQ (UMBRALISIB) — SAD**L 05/01/2017

    - C9399 — VANFLYTA (QUIZARTINIB) — SAD**L 02/05/2021

    - C9399 — VARITHENA (POLIDOCANOL INJECTABLE FOAM) — SAD**L 07/28/2023 — COMMENTS: Drug not separately allowed, bundled within.

    - J1559 — HIZENTRA (HUMAN IMMUNE GLOBULIN) — DRUG DATE 04/01/2010

    - J1561 — GAMMAKED / GAMUNEX / GAMUNEX-C (HUMAN IMMUNE GLOBULIN) — various SAD flags and dates

    - J1562 — VIVAGLOBIN — DRUG DATE 03/01/2006 — COMMENTS: product discontinued

    - J1599 — YIMMUGO / Unclassified IVIG — DRUG DATE 06/13/2024

    - J1930 — SOMATULINE DEPOT (LANREOTIDE) — PADP X — DRUG DATE 04/15/2010

    - J2323 — TYSABRI (NATALIZUMAB) — PADP X — DRUG DATE 03/15/2008

    - J2326 — SPINRAZA (NUSINERSEN) — DRUG DATE 12/28/2016

    - J2506 — NEULASTA (PEGFILGRASTIM) — SAD flags — DRUG DATE 04/01/2002

    - J2778 — LUCENTIS (RANIBIZUMAB) — DRUG DATE 10/15/2007

    - J2820 — LEUKINE (SARGRAMOSTIM) — SAD flags — DRUG DATE 11/14/2016

    - J2941 — GENOTROPIN / HUMATROPE / NORDITROPIN (SOMATROPIN) — SAD** flags

    The provided catalog does not include explicit coverage exclusions or determinations of “not medically necessary.” It functions as a mapping of codes to drug entries and internal flags. Any coverage determinations (including exclusions or medical necessity denials) are made based on the member's benefit plan, medical necessity criteria, and any applicable prior authorization or utilization management policies.

    Additional provider guidance:

    - Verify member eligibility and benefits prior to service.

    - Confirm whether the member's plan requires prior authorization for the specific drug and administration route.

    - Check if the drug is processed under the pharmacy benefit versus the medical benefit; prior authorization processes differ by benefit type.

    Where entries indicate “Drug not separately allowed, bundled within,” the drug is considered part of another procedure or service for billing purposes and is not eligible for separate reimbursement. Providers should:

    - Review the applicable procedure or bundle billing guidance before submitting claims.

    - Confirm with the payer if separate reimbursement is appropriate in exceptional circumstances and obtain prior authorization when required.

    This section contains only code-to-drug mappings and administrative flags. It does not itself establish clinical coverage rules or exclusions. Coverage is determined by the applicable benefit contract and utilization management policies.

    Drugs included in the HCPCS/J-code catalog may be subject to plan-specific coverage limitations. Prior to providing services or submitting claims, verify:

    - Member eligibility and plan benefits via Eligibility & Benefits (E&B) systems.

    - Whether the drug is covered under the medical benefit or the pharmacy benefit.

    - Any prior authorization, step therapy, quantity limits, or other utilization management requirements.

    This segment is informational and lists HCPCS/CPT codes with associated drug names and administrative flags. It does not provide clinical criteria or medical necessity rules. For clinical coverage criteria, refer to the payer's utilization management and medical necessity policy documents.

    The provided content does not include determinations of procedures or drugs being 'not medically necessary.' Coverage decisions of that nature are handled through separate clinical policy documents and prior authorization determinations.

    This document section is a catalog-style listing used for reference mapping of HCPCS/CPT codes to drug brand names, generic equivalents, and internal administrative flags (PADP, CEI, SAD) along with effective or listed dates. It is maintained to support coding, billing, and prior authorization workflows. Updates to codes and new drug approvals may be reflected periodically; always confirm current coding and coverage status before billing.

    HCPCS/CPT/Q-code listings and mappings

    Listed HCPCS/CPT/Custom codes and mapped entriesmixedCovered
    90281GamaSTAN SID / IMMUNE GLOBULIN
    90283CARIMUNE NF / FLEBOGAMMA / GAMMAGARD / GAMMAGARD SD / GAMMAKED / GAMMAPLEX / GAMUNEX / GAMUNEX-C / OCTAGAM / PRIVIGEN (IMMUNE GLOBULIN variants)
    90284CUVITRU / GAMMAGARD LIQUID / GAMMAKED / GAMUNEX-C / HIZENTRA / HYQVIA (IMMUNE GLOBULIN variants)
    90378SYNAGIS / PALIVIZUMAB
    90399-Unlisted IVIG (IMMUNE GLOBULIN)
    A9156*ORAL MUCOADHESIVE, ANY TYPE (A9156*)
    A9513LUTATHERA / LUTETIUM LU 177
    A9543ZEVALIN / IBRITUMOMAB TIUXETAN
    A9590AZEDRA / IODINE I-131 IOBENGUANE
    A9600METASTRON / STRONTIUM SR-89 CHLORIDE
    1–10 of 29
    1/3
    HCPCS / placeholder codesHCPCS
    C9399HCPCS miscellaneous drug code used as placeholder for many specialty drugs listed
    J3392New HCPCS referenced effective 01/01/2025 (document notes)
    Q5143New HCPCS referenced effective 01/01/2025 (document notes)
    Q5140New HCPCS referenced effective 01/01/2025 (document notes)
    C9399 EntriesHCPCS
    C9399Unclassified drugs — multiple drug name entries listed under C9399
    69399 / Q-code noteHCPCS
    69399New HCPCS, Q5141 effective 01/01/2025 (note in document)
    Listed J-/G-/C- HCPCS codesHCPCS
    G0138OPFOLDA & POMBILITI ADM (documented)
    J0129ORENCIA IV / ABATACEPT
    J0139HUMIRA / ADALIMUMAB
    J0172ADUHELM / ADUCANUMAB-AVWA
    J0174LEQEMBI / LECANEMAB-IRMB
    J0175KISUNLA / DONANEMAB-AZBT
    J0177EYLEA HD / AFLIBERCEPT
    J0178EYLEA / AFLIBERCEPT
    J0179BEOVU / BROLUCIZUMAB-DBLL
    J0180FABRAZYME / AGALSIDASE BETA
    1–10 of 46
    1/5
    New/Updated J‑codes (sample from chunk)HCPCS
    J0597BERINERT (entry shows J0597 with notes)
    J0598CINRYZE (C1 ESTERASE INHIBITOR)
    J0599HAEGARDA (ESTERASE INH)
    Soliris HCPCS mappingHCPCS
    J1299SOLIRIS (ECULIZUMAB)
    J4300SOLIRIS (ECULIZUMAB) - new HCPCS
    Gene therapy J‑codesHCPCS
    J1411HEMGENIX (TRANACOGENE DEZAPARVOVEC-DRLB)
    J1412ROCTAVIAN (VALOCTOCOGENE ROXAPARVOVEC)
    J1413ELEVIDYS (DELANDISTROGENE MOXEPARVOVEC)
    Infusion/biologic J‑codesHCPCS
    J1437MONOFERRIC (FERRIC DERISOMALTOSE)
    J1438ENBREL (ETANERCEPT)
    J1442NEUPOGEN (FILGRASTIM)
    Immune globulin / IVIG related J-codesHCPCS
    J1558listed (no drug name in these chunks)
    J1559HIZENTRA / HUMAN IMMUNE GLOBULIN
    J1561GAMMAKED / GAMUNEX / GAMUNEX-C (HUMAN IMMUNE GLOBULIN)
    J1562VIVAGLOBIN (HUMAN IMMUNE GLOBULIN)
    Additional immune and neurologic agentsHCPCS
    J1566CARIMUNE NF / GAMMAGARD SD / PANGLOBULIN NF (HUMAN IMMUNE GLOBULIN)
    J1568OCTAGAM (HUMAN IMMUNE GLOBULIN)
    J1569GAMMAGARD LIQUID
    J1572FLEBOGAMMA (HUMAN IMMUNE GLOBULIN)
    J1575HYQVIA (IMMUNE GLOBULIN)
    J1576PANZYGA (IMMUNE GLOBULIN IV)
    J1595COPAXONE / GLATIRAMER / GLATOPA (GLATIRAMER ACETATE)
    Mixed specialty injectablesHCPCS
    J1599YIMMUGO / Unclassified IVIG (IMMUNE GLOBULIN IV)
    J1602SIMPONI ARIA (GOLIMUMAB)
    J1627SUSTOL (GRANISETRON)
    J1628TREMFYA SQ / TREMFYA IV (GUSELKUMAB)
    J1632ZULRESSO (BREXANOLONE)
    J4645FRAGMIN (DALTEPARIN SODIUM)
    Immunomodulators and biologicsHCPCS
    J1726MAKENA (HYDROXYPROGESTERONE CAPROATE)
    J1729HYDROXY- (HYDROXYPROGESTERONE CAPROATE)
    J1743ELAPRASE (IDURSULFASE)
    J1744FIRAZYR (ICATIBANT)
    J1745REMICADE (INFLIXIMAB)
    J1747SPEVIGO (SPESOLIMAB)
    J1748ZYMFENTRA (INFLIXIMAB-DYYB)
    Enzyme replacement, MS drugs, and somatostatin analogHCPCS
    J1786CEREZYME (IMIGLUCERASE)
    J1823UPLIZNA (INEBILIZUMAB-CDON)
    J1826AVONEX (INTERFERON BETA-1A)
    J1830BETASERON / EXTAVIA (INTERFERON BETA-1B)
    J1930SOMATULINE DEPOT (LANREOTIDE)
    J1931ALDURAZYME (LARONIDASE)
    Hormonal, respiratory, and supportive care agentsHCPCS
    J1932CIPLA (LANREOTIDE)
    J1941FUROSCIX (FUROSEMIDE)
    J1950LUPRON DEPOT / FENSOLVI / CAMCEVI / LUTRATE (LEUPROLIDE variants)
    J2170INCRELEX (MECASERMIN)
    J2182NUCALA (MEPOLIZUMAB)
    J2212RELISTOR (METHYLNALTREXONE)
    Neurology/oncology/immunology biologicsHCPCS
    J2267OMVOH IV (MIRIKIZUMAB-MRKZ IV)
    J2277APHEXDA (MOTIXAFORTIDE)
    J2323TYSABRI (NATALIZUMAB)
    J2326SPINRAZA (NUSINERSEN)
    J2327SKYRIZI IV (RISANKIZUMAB-RZAA)
    J2329BRIUMVI (UBLITUXIMAB)
    Allergy, endocrine, and biologic injectablesHCPCS
    J2350OCREVUS (OCRELIZUMAB)
    J2351OCREVUS ZUNOVO (OCRELIZUMAB; HYALURONIDASE-OCSQ)
    J2353SANDOSTATIN LAR (OCTREOTIDE)
    J2355NEUMEGA (OPRELVEKIN)
    J2356TEZSPIRE / TEZSPIRE PEN (TEZEPELUMAB-EKKO)
    J2357XOLAIR (OMALIZUMAB)
    Supportive oncology and related injectablesHCPCS
    J2469ALOXL (PALONOSETRON)
    J2502SIGNIFOR LAR (PASREOTIDE LONG ACTING)
    J2503MACUGEN (PEGAPTANIB SODIUM)
    J2506NEULASTA (PEGFILGRASTIM)
    J2507KRYSTEXXA (PEGLOTICASE)
    J2508ELFABRIO (PEGUNIGALSIDASE ALFA-IWXJ)
    Ophthalmology and supportive biologicsHCPCS
    J2562MOZOBIL (PLERIXAFOR)
    J2675Progesterone in Oil (PROGESTERONE)
    J2724CEPROTIN (PROTEIN C CONCENTRATE)
    J2777VABYSMO (FARICIMAB-SVOA)
    J2778LUCENTIS (RANIBIZUMAB)
    J2779SUSVIMO (RANIBIZUMAB)
    Ophthalmic and other specialty agentsHCPCS
    J2781SYFOVRE (PEGCETACOPLAN)
    J2782IZERVAY (AVACINCAPTAD PEGOL)
    J2783ELITEK (RASBURICASE)
    J2786CINQAIR (RESLIZUMAB)
    J2787PHOTREXA VISCOUS (RIBOFLAVIN 5-PHOSPHATE)
    J2788HYPER RHO SD Mini (product unspecified)
    Immune and hematology agentsHCPCS
    J2790HYPER RHO SD
    J279+RHOPHYLAG (RHO D IMMUNE GLOBULIN)
    J2793ARCALYST (RILONACEPT)
    J2802NPLATE (ROMIPLOSTIM)
    J2820LEUKINE (SARGRAMOSTIM GM-CSF)
    Enzyme replacement and growth hormone productsHCPCS
    J2840KANUMA (SEBELIPASE ALFA)
    J2860SYLVANT (SILTUXIMAB)
    J2941GENOTROPIN / HUMATROPE / NORDITROPIN (SOMATROPIN)
    Listed HCPCS codes (partial, start of excerpt)HCPCS
    J2792DRUG NAME = .
    J2793DRUG NAME = ARCALYST (RILONACEPT)
    J2796DRUG NAME = .
    J2797DRUG NAME = VARUBI (ROLAPITANT)
    J2802DRUG NAME = NPLATE (ROMIPLOSTIM)
    J2820DRUG NAME = LEUKINE (SARGRAMOSTIM GM-CSF)
    Listed HCPCS codes (somatropin and others)HCPCS
    J2840DRUG NAME = KANUMA (SEBELIPASE ALFA)
    J2860DRUG NAME = SYLVANT (SILTUXIMAB)
    J2941DRUG NAME(S) = GENOTROPIN, HUMATROPE, NORDITROPIN, NUTROPIN, OMNITROPE, SAIZEN, SEROSTIM, TEVTROPIN, ZOMACTON, ZORBTIVE (SOMATROPIN and related)
    J2998DRUG NAME = RYPLAZIM (PLASMINOGEN, HUMAN-TVMH)
    Listed HCPCS codes (migraine/biologic/enzymes/hormones)HCPCS
    J3031DRUG NAME = AJOVY (FREMANEZUMAB‑VRFRM)
    J3032DRUG NAME = VYEPTI (EPTINEZUMAB‑JJMR)
    J3055DRUG NAME = TALVEY (TALQUETAMAB‑TGVS)
    J3060DRUG NAME = ELELYSO (TALIGLUCERASE ALFA)
    J3110DRUG NAME = FORTEO (TERIPARATIDE)
    J3111DRUG NAME = EVENITY (ROMOSOZUMAB‑AQQG)
    Listed HCPCS codes (immunologic/infusion agents)HCPCS
    J3145DRUG NAME = AVEED (TESTOSTERONE UNDECANOATE)
    J3241DRUG NAME = TEPEZZA (TEPROTUMUMAB‑TRBW)
    J3245DRUG NAME = ILUMYA (TILDRAKIZUMAB‑ASMN)
    J3247DRUG NAME = COSENTYX IV (EXAGAMGLOGENE AUTOTEMCEL IV)
    J3262DRUG NAME = ACTEMRA IV (TOCILIZUMAB IV)
    J3285DRUG NAME = REMODULIN (TREPROSTINIL)
    Listed HCPCS codes (hormones/biologics)HCPCS
    J3299DRUG NAME = XIPERE (TRIAMCINOLONE ACETONIDE)
    J3304DRUG NAME = ZILRETTA (TRIAMCINOLONE)
    J3315DRUG NAME = TRELSTAR DEPOT / LA (TRIPTORELIN PAMOATE / ER)
    J3316DRUG NAME = TRIPTODUR (TRIPTORELIN ER)
    J3357DRUG NAME = STELARA SQ / IV (USTEKINUMAB)
    J3380DRUG NAME = ENTYVIO (VEDOLIZUMAB)
    Listed HCPCS codes (gene/cell and enzyme therapies)HCPCS
    J3385DRUG NAME = VPRIV (VELAGLUCERASE ALFA)
    J3392DRUG NAME = CASGEVY (EXAGAMGLOGENE AUTOTEMCEL)
    J3393DRUG NAME = ZYNTEGLO (BETIBEGLOGENE AUTOTEMCEL)
    J3394DRUG NAME = LYFGENIA (LOVOTIBEGLOGENE AUTOTEMCEL)
    J3396DRUG NAME = VISUDYNE (VERTEPORFIN)
    J3397DRUG NAME = MEPSEVII (VESTRONIDASE ALFA‑VJBK)
    Listed HCPCS codes (gene therapies and miscellaneous J3490 entries)HCPCS
    J3398DRUG NAME = LUXTURNA (VORETIGENE NEPARVOVEC‑RZYL)
    J3399DRUG NAME = ZOLGENSMA (ONASEMNOGENE ABEPARVOVEC‑XIOI)
    J3401DRUG NAME = VYJUVEK (BEREMAGENE GEPERPAVEC‑SVDT)
    J3420DRUG NAME = B+ (GYANOCOBALAMIN)
    J3489DRUG NAME = (ZOLEDRONIG AGID) [text fragmented]
    J3490DRUG NAME = AIMOVIG (ERENUMAB‑AOOE) and many additional drugs listed under J3490 placeholder
    Miscellaneous J-code entriesHCPCS
    J3490Unclassified drugs / miscellaneous injectable drug code
    Miscellaneous and new HCPCS/Q-codesHCPCS
    J3590Unclassified biologic or other drug code (miscellaneous)
    Q5150New HCPCS (noted effective 04/01/2025) — referenced in document
    J1414New HCPCS referenced (effective 01/01/2025)
    Q5139New HCPCS referenced (effective 01/01/2025)
    J3392New HCPCS referenced (effective 01/01/2025)
    Q5143New HCPCS referenced (effective 01/01/2025)
    Q5149New HCPCS referenced (effective 04/01/2025)
    Q5151New HCPCS referenced (effective 04/01/2025)
    Q5140New HCPCS referenced (effective 01/01/2025)
    Specific J-code assignmentsHCPCS
    J3535INBRIJA (levodopa) listed under J3535
    J3520EDTA (edetate disodium) listed under J3520
    Listed HCPCS/J-codes and associated drug descriptionsHCPCS
    J3590Unclassified drugs / placeholder HCPCS referenced for many newly added drugs
    J7170HEMLIBRA (emicizumab-kxwh)
    J7171ADZYNMA (adamts13, recombinant-krhn)
    J7175COAGADEX (factor X)
    J7177FIBRYGA (human fibrinogen concentrate)
    J7178RIASTAP (human fibrinogen concentrate)
    J7179VONVENDI (von Willebrand factor)
    J7180CORIFACT (factor XIII concentrate)
    J7181TRETTEN (factor XIII A-subunit)
    J7182NOVOEIGHT (factor VIII)
    1–10 of 29
    1/3
    Hemophilia/clotting factor HCPCS codesHCPCSCovered
    J7193DRUG = nla
    J7194PROFILNINE SD (FACTOR IX)
    J7195BENEFIX (FACTOR IX)
    J7198FEIBA (ANTI-INHIBITOR COAGUALTION)
    J7199*Unclassified FACTOR (HEMOPHILIA CLOTTING FACTOR, NOT)
    J7200RIXUBIS (FACTOR IX)
    J7201ALPROLIX (FACTOR IX)
    J7202IDELVION (FACTOR IX)
    J7203REBINYN (FACTOR IX, GLYCOPEGYLATED)
    J7204ESPEROCT (FACTOR VIII, GLYCOPEGYLATED-EXEI)
    1–10 of 15
    1/2
    Ophthalmic implant HCPCS codesHCPCSCovered
    J7212SEVENFACT (FACTOR VIIA-JNCW)
    J7213IXINITY (FACTOR IX)
    J7214ALTUVIIIO (HEMOPHILIA CLOTTING FACTOR, NOT)
    J7311RETISERT (FLUCINOLONE ACETONIDE)
    J7312OZURDEX (DEXAMETHASONE)
    J7313ILUVIEN (FLUOCINOLONE ACETONIDE)
    J7314YUTIQ (FLUOCINOLONE ACETONIDE)
    Intra-articular / hyaluronan and tissue product HCPCS codesHCPCSCovered
    J7318DUROLANE (HYALURONAN DERIVATIVE)
    J7320GENVISC 850 (HYALURONAN/DERIVATIVE)
    J7321HYALGAN / SUPARTZ / VISCO-3 (SODIUM HYALURONATE)
    J7324ORTHOVISC (HIGH MOLECULAR WEIGHT)
    J7325SYNVISC / SYNVISC ONE (HYLAN G-F 20)
    J7326GEL-ONE (CROSS-LINKED HYALURONATE)
    J7327MONOVISC (HIGH MOLECULAR WEIGHT)
    J7328GEL-SYN (HYALURONAN DERIVATIVE)
    J7329TRIVISC (HYALURONAN DERIVATIVE)
    J7330MACI (AUTOLOGOUS CULTURED)
    1–10 of 12
    1/2
    Misc local/injectable HCPCS codesHCPCSCovered
    J7352SCENESSE (AFAMELANOTIDE)
    J7354YCANTH (CANTHARIDIN)
    J7355IDOSE TR (TRAVOPROST INTRACAMERAL)
    J7402SINUVA IMPLANT (MOMETASONE FUROATE) - PADP = X
    J7514MYHIBBIN (MYCOPHENOLATE MOFETIL)
    Inhalation, NOC, and oral oncology HCPCS codesHCPCSCovered
    J7601OHTUVAYRE (ENSIFENTRINE)
    J7686TYVASO (TREPROSTINIL INHALATION)
    J7699NOC INHALATION
    J7799*NOC OTHER THAN
    J7999NOC (FINAL COMPOUNDED PRODUCT)
    J8499MACRILEN / Oral Non-Chemo
    J8520XELODA (GAPEGHFABINE) - note new HCPCS J8522 effective 10/01/2025
    J8524XELODA (GAPECHFABINE)
    J8522XELODA (CAPECITABINE)
    Oncology and infusion HCPCS codes (J90xx–J90xx+)HCPCSCovered
    J8611JYLAMVO (METHOTREXATE)
    J8612XATMEP (METHOTREXATE)
    J8655AKYNZEO (NETUPITANT and PALONOSETRON)
    J8700TEMODAR (TEMOZOLOMIDE)
    J8705HYCAMTIN ORAL (TOPOTECAN)
    J8999Oral Chemo (ORAL CHEMO PRESCRIPTION DRUG)
    J9019ERWINAZE (ASPARAGINASE) - PADP = X
    J9021RYLAZE (ASPARAGINASE ERWINIA) - PADP = X
    J9022TECENTRIQ (ATEZOLIZUMAB) - PADP = X
    J9023BAVENCIO (AVELUMAB) - PADP = X
    1–10 of 34
    1/4
    Newly listed J-codes (sample block)HCPCS
    J9046BORTEZOMIB / BORFEZOMIB (multiple entries)
    J9047KYPROLIS / CARFILZOMIB
    J9048BORTEZOMB / BORTEZOMIB
    J9049BORTEZOAAB
    J9055ERBITUX / CETUXIMAB
    Newly Added Drug or Newly FDA Approved Drug - full listHCPCS
    J9056VIVIMUSTA / BENDAMUSTINE HYDROCHLORIDE
    J9057ALIQOPA / COPANLISIB
    J9058BENDAMUSTINE
    J9063ELAHERE / MIRVETUXIMAB-SORAVTANSINE-GYNX
    J9064CABAZITAXEL
    J9118ASPARLAS / CALASPARGASE PAGOL-MKNL
    J9119LIBTAYO / CEMIPLIMAB-RWIC
    J9144DARZALEX FASPRO / DARATUMUMAB & HYALURONIDASE-FIHJ
    J9145DARZALEX / DARATUMUMAB
    J9153VYXEOS / DAUNORUBICIN and CYTARABINE
    1–10 of 77
    1/8

    Prior authorization, billing, and submission guidance

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required or implied for many listed specialty drugs and HCPCS/J-code billed drugs. Providers must verify member benefits and submit prior authorization requests to the appropriate Florida Blue vendor or PBM based on place of service, billing entity, and member product type before administering or billing the drug. Failure to obtain prior authorization when required may result in denial and financial liability.

    • Prior authorization implied for listed specialty drugs and PADP‑managed drugs.
    • Prior authorization applies to the HCPCS and J‑code drug listings in this section (see code groups for specific codes).
    • Newly FDA‑approved or newly coded drugs may be subject to prior authorization even if not yet listed — verify benefits.
    Documentation Required

    Where to Submit Prior Authorization

    Submit medical/specialty pharmacy prior authorization requests to the Florida Blue vendor or PBM responsible for the member’s product and the drug’s routing: Caremark/OptumRx for pharmacy‑benefit managed drugs; Prime Therapeutics (MRxM) for PADP/Prime specialty pharmacy managed drugs; CareCentrix for home infusion/home health/AIS network services; Availity, Blue Express, or Florida Blue provider portals/phone lines for other medical benefit submissions. Use the entity billing drug and place of service to determine routing.

    Terms and internal flags

    C‑codes applicability
    C-codes usage restrictionDocument explicitly states: 'C-codes only applicable for Outpatient Facility.'
    Context in listingC9399 and related C-code entries include the C-code applicability note and are used in the outpatient facility setting.
    Provider actionBill C-code items only when the service is provided in an outpatient facility Place of Service to align with coding guidance.
    PADP program flag
    PADP flag indicates program managementMany entries are marked with 'PADP = X' or list PADP fields (examples: C9473 PADP = X; Q5111 entries show PADP fields); PADP marks drugs as subject to the payer's PADP-managed program.
    Widespread presencePADP annotations appear across HCPCS, J-, and Q-code listings throughout the document indicating program-managed drugs are common in the list.

    Step therapy and PBM-managed prior authorization notes

    Coverage itemDetail
    Some products require prior approval via a PBM or Prime Therapeutics
    Refer to Caremark or OptumRx for pharmacy benefit prior approvals; Prime Therapeutics (formerly MRxM) handles many medical‑benefit specialty drug requests (provider self‑service gatewaypa.com or phone) — submission routing depends on entity billing and place of service
    Step therapy specifics and required trial/failure sequences are not provided in this excerpt
    Step therapy observationSource note
    No explicit step therapy rules provided in these chunks
    Entries include PADP and CEL flags indicating some drugs are managed under payer programs; program-managed drugs may have separate prior‑authorization or step requirements not listed here
    ObservationImplication for providers
    No step therapy sequences are specified in this excerpt; many products are listed under miscellaneous J‑codes (e.g., J3490) or placeholders requiring provider mapping to the specific drug
    When a drug is billed under a miscellaneous code (J3490/J3590) providers must map the administered product to the appropriate HCPCS/Q code and follow PADP/CEL/SAD flags; specific step‑therapy enforcement is determined by the program managing the drug and is not described here

    Place of service and routing

    Prior Authorization

    Route PA by Place of Service and rendering entity

    Place of Service and Rendering Entity Participation Status influence which vendor handles the prior authorization; home infusion/home health and AIS routes may require CareCentrix coordination when participating in the CCX network.

    • For home infusion/home health/AIS participating in CCX: route reviews coordinated with CareCentrix (phone/fax as provided).
    Note
    Note
    Policy Summary
    PayerFlorida Blue
    PolicyMedical/Specialty Pharmacy Drugs Requiring Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2025
    Last ReviewApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to the vendor identified by Place of Service, Rendering Entity Participation Status, Specific Drug, and Member Product Type (e.g., Prime Therapeutics, Caremark/OptumRx, CareCentrix, Availity/Blue Express).
    SourceLink
    On This Page
    Coverage criteria and listingHCPCS/CPT/Q-code listings and mappingsPrior authorization, billing, and submission guidanceTerms and internal flagsStep therapy and PBM-managed prior authorization notesPlace of service and routing

    - J3490 / J3590 — Unclassified or miscellaneous drug codes (e.g., TOSYMRA, TRYNGOLZA, TYMLOS, VARITHENA, NEMLUVIO, NGENLA, NYPOZI) — various PADP/CEL/SAD flags and dates — some entries include: COMMENTS: Drug not separately allowed, bundled within.

    Notes:

    - Self-administered drugs may have limited benefits when billed through the medical benefit.

    - New drugs approved by the FDA may not be listed immediately but could be subject to prior authorization.

    - Drugs listed may not be covered by the member's benefits; verify eligibility and benefits before providing services.

    - When new codes are assigned to drugs, search by HCPCS/CPT code and/or drug brand name to confirm processing and coverage.

    New J-series HCPCS entriesHCPCS
    J9314
    J9316PHESGO (pertuzumab, trastuzumab, and ...)
    J9317TRODELVY (sacituzumab)
    J9318ROMIDEPSIN, non-lyophilied
    J9319ISTODAX (romidepsin, lyophilied)
    Additional J-series HCPCSHCPCS
    J9321EPKINLY (epcoritamab-bysp)
    J9322PEMETREXED
    J9323PEMETREXED
    J9324PEMRYDI RTU (pemetrexed)
    J9325IMLYGIC (talimogene laherparepvec)
    J9332VYVGART (efgartigimod alfa-fcab)
    Further J-series HCPCSHCPCS
    J9333RYSTIGGO (rozanolixizumab-noli)
    J9334YVGART HYTRULO (efgartigimod alfa-fcab)
    J9345ZYNYZ (retifanlimab-dlwr)
    J9347IMJUDO (tremelimumab-actl)
    J9348DANYELZA (naxitamab-cmkb)
    J9349MONJUVI (tafasitamab-cxix)
    Her2 and related agents (J-series)HCPCS
    J9350LUNSUMIO (mosunetuzumab-axgb)
    J9352YONDELIS (trabectedin)
    J9353MARGENZA (margetuximab-cmkb)
    J9354KADCYLA (ado-trastuzumab)
    J9355HERCEPTIN (trastuzumab)
    J9356HERCEPTIN HYLECTA (trastuzumab hyaluronidase-oysk)
    Additional J-series entriesHCPCS
    J9358ENHERTU (fam-trastuzumab deruxtecan-nxki)
    J9361RYZNEUTA (efbemalenograstim alfa-vuxw)
    J9376VEOPOZ (pozelimab-bbfg)
    J9380TECVAYLI (teclistamab-cqyv)
    J9381TZIELD (teplizumab-mzwv)
    J9395FASLODEX (fulvestrant)
    J9400ZALTRAP (ziv-aflibercept)
    Unclassified J9999 placeholdersHCPCS
    J9999AMTAGVI / multiple unclassified or newly added specialty drugs (placeholder)
    Q-code cell and gene therapy entriesHCPCS
    Q2041YESCARTA (axicabtagene ciloleucel)
    Q2042KYMRIAH (tisagenlecleucel)
    Q2043PROVENGE (sipuleucel-T autologous CD54+)
    Q2049LIPODOX (doxorubicin liposomal)
    Q2050DOXIL (doxorubicin liposomal)
    Q2053TECARTUS (brexucabtagene autoleucel)
    Q2054BREYANZI CD4 (lisocabtagene maraleucel)
    Q2055ABECMA (idecabtagene vicleucel)
    Q2056CARVYKTI (ciltacabtagene autoleucel)
    Q2057TECELRA (afamitresgene autoleucel)
    Q5xxx biologic/biosimilar and support drug codesHCPCS
    Q3028REBIF / VENTAVIS / interferon beta-1a entries
    Q4082*Unclassified Rx*
    Q5101ZARXIO (filgrastim-sndz)
    Q5103INFLECTRA (infliximab-dyyb)
    Q5104INFLECTRA / RENFLEXIS entries
    Q5106RETACRIT (epoetin alfa) / PADP = X
    Q5107MVASI (bevacizumab-awwb)
    Q5108FULPHILA (pegfilgrastim-jmdb)
    Q5109IXIFI (infliximab-qbtx)
    Q5110NIVESTYM (filgrastim-aafi)
    1–10 of 14
    1/2
    Newly added / newly FDA-approved HCPCS, Q, and S codes listed in this sectionmixed
    Q5106RETACRIT / EPOETIN ALFA
    Q5107MVASI / BEVACIZUMAB-AWWB
    Q5108FULPHILA / PEGFILGRASTIM-JMDB
    Q5109IXIFI / INFLIXIMAB-QBTX
    Q5110NIVESTYM / FILGRASTIM-AAFI
    Q5111UDENYCA / PEGFILGRASTIM-CBQV (including ONBODY 01/23/2024)
    Q5112ONTRUZANT / TRASTUZUMAB-DTTB
    Q5113HERZUMA / TRASTUZUMAB-PKRB
    Q5114OGIVRI / TRASTUZUMAB-DKST
    Q5115TRUXIMA / RITUXIMAB-ABBS
    1–10 of 61
    1/7
    Effective dates / new HCPCS activation
    Multiple new HCPCS effective datesDocument shows multiple HCPCS activation dates (examples: codes noted as effective 01/01/2025 and 04/01/2025; see per-entry 'DRUG =' dates).
    Specific example — 01/01/2025Several entries indicate new HCPCS mappings effective 01/01/2025 (e.g., comments: 'New HCPCS, J9028 effective 01/01/2025'; 'J9026 effective 01/01/2025'; J2802 effective 01/01/2025).
    Specific example — 04/01/2025Some Q‑codes are noted with 04/01/2025 effective dates (examples in comments: Q5152 effective 04/01/2025; J2351 effective 04/01/2025).
    Per-entry drug added datesMany lines include the drug 'DRUG =' date showing when the drug entry was added (examples: J9316 DRUG = 06/29/2020; J1561 DRUG = 10/09/2003).
    New oral oncology HCPCS activationComments indicate J8522 (capecitabine) mapped/new HCPCS effective 10/01/2025 (noted as 'J8522 effective 10/01/2025').
    No numeric thresholds in this segment
    No numeric thresholds presentThis segment contains HCPCS/Q-code listings and per-entry dates/flags but does not specify numeric clinical or utilization thresholds (e.g., dose limits, quantities).
    Listing natureEntries are code-to-drug mappings with PADP/CEI/SAD flags and added/effective dates; no numeric limits are provided here.
    Action for providersVerify plan-specific benefit and prior authorization rules elsewhere; do not rely on this listing for numeric limit information.
    No numeric clinical thresholds in this excerpt
    No clinical numeric thresholdsThe excerpt is a catalog of HCPCS/J-code entries and internal flags and does not include numeric clinical thresholds (e.g., lab value cutoffs, duration limits).
    Clinical guidance absentNo explicit medical necessity criteria or numeric clinical entry requirements are provided in these chunks.
    Provider implicationClinical eligibility and numeric thresholds must be confirmed in the master policy or product-specific criteria; this list is identification only.
    New HCPCS effective date note — J8522
    J8522 effective dateComment in listing: 'HCPCS, J8522 effective 10/01/2025' associated with J8520/J8524 entries for capecitabine/XELODA mapping.
    Related entriesJ8520 and J8524 entries reference the new HCPCS J8522 in comments indicating the effective mapping date.
    Provider noteWhen billing oral capecitabine products, use the HCPCS mapping consistent with the J8522 effective date once active to avoid claim issues.
    Effective / Added date (per-entry examples)
    Per-entry 'DRUG =' added datesMany entries include the exact 'DRUG =' added date (example: J9316 DRUG = 06/29/2020; multiple immune globulin entries include DRUG = 04/01/2010, 08/03/2011, etc.).
    Example — immune globulin entriesJ1559 HIZENTRA DRUG = 04/01/2010; J1561 GAMMAKED DRUG = 08/03/2011; J1561 GAMUNEX-C DRUG = 12/07/2010.
    Example — oncology biologicsJ9316 PHESGO DRUG = 06/29/2020; J9317 TRODELVY DRUG = 04/22/2020.
    Effective date notes — Q-code examples
    Q5xxx examples with effective datesEntries note specific Q-code effective assignments: e.g., comments show 'New HCPCS, Q5144 effective 01/01/2025' and 'New HCPCS, Q5152 effective 04/01/2025'.
    Q5140/Q5141/Q5143 referencesMultiple Q514x entries (Q5140, Q5141, Q5143, Q5144, Q5149, Q5150, etc.) are listed with comments indicating new HCPCS status and associated dates in the document.
    Provider billing implicationUse newly assigned Q-codes starting on their effective dates and ensure claims reflect the correct HCPCS/Q-code when available.
    • Prime Therapeutics provider self‑service: https://gatewaypa.com (physician tab) or (800) 424‑4947.
    • CareCentrix Phone: (877) 561‑9910 Fax: (877) 627‑6688.
    • Prime Therapeutics (Part D/MedAdv/other lines): phone/fax numbers listed in vendor guidance.
    Billing Rule

    Billing and HCPCS/J‑code Guidance

    J‑codes, miscellaneous J‑codes (J3490/J3590/J9999) and unclassified HCPCS entries are included in the catalog as mapping records; presence in the list often triggers prior authorization tracking or PADP management. Providers must bill using the assigned specific HCPCS/Q/J code when available — using a miscellaneous/unlisted J‑code when a specific HCPCS exists can affect adjudication and PA processing.

    • Use the assigned HCPCS/Q/J code when billed; avoid J3490/J3590/J9999 if a specific code exists.
    • Unclassified Rx/Forgotten mapping entries are present (e.g., J3490 entries for infertility and other drugs) — review code mapping before billing.
    • New HCPCS assignments with effective dates are noted; ensure claim dates align with HCPCS effective dates.
    Note

    PADP / Program Management Flags

    PADP (Prime/ MRxM) managed drugs and PADP‑marked codes may require prior authorization and/or program enrollment. PADP flags and CEL/SAD annotations identify program management level, required enrollment, and historical effective dates for codes; verify the PADP/CEL/SAD indicators and follow enrollment requirements where marked.

    • PADP = X indicates PADP management; review and submit to Prime/ MRxM when indicated.
    • CEL/SAD flags denote additional program flags or historical notes — reference the PADP/CEL/SAD fields for operational requirements.
    • PADP‑marked drugs may require provider enrollment in specialty programs or specific vendor routing.
    Documentation Required

    Documentation and Claim Submission Requirements

    Document drug name, generic/alternate name, applicable HCPCS/Q/J code and the date of service on authorization and claim submissions. For newly assigned HCPCS/Q codes, include the drug brand name and confirm the HCPCS effective date to avoid billing code/date mismatch denials.

    • Required claim and drug mapping details: drug name, generic alternate, HCPCS/Q/J code, effective date.
    • Billing code/date mismatch risk — ensure the HCPCS effective date matches claim DOS.
    • If a new HCPCS/Q code exists for a drug, do not submit under miscellaneous J‑codes; document the specific code on the authorization and claim.
    Note

    Scope and Limitations of This Listing

    This section is primarily a registry/catalog of HCPCS/J codes mapped to drug names and management flags; it does not enumerate detailed authorization criteria, step‑therapy sequences, or explicit denial rules. Providers must verify benefit coverage and follow the specific prior authorization program rules for each drug as indicated by PADP/CEL/SAD flags or by contacting the applicable vendor.

    • No explicit authorization/denial rules or step‑therapy algorithms are provided in this excerpt — refer to the vendor/PBM policy for criteria.
    • Benefit verification is required prior to service: confirm member benefits and medical necessity.
    • When criteria are required, follow the vendor/PBM prior authorization checklist for supporting documentation.
    Denial Risk

    Provider Actions and Denial Risks

    Provider actions to reduce denial risk: verify member benefits and product coverage before service; use specific HCPCS/Q/J codes when available; route prior authorization to the correct vendor; and include complete clinical documentation with PA requests. Be alert for HCPCS effective date mismatches and for bundled billing situations where drug supply may be included in another payment.

    • Benefit verification required — check eligibility and benefits prior to providing services.
    • Bundled billing: some drugs may be bundled with procedures — review billing guidelines to avoid denials.
    • Provider must bill using the listed HCPCS/J‑code corresponding to the drug administered.
    Provider implicationEntries with PADP marking may require prior authorization or program enrollment per the payer's PADP procedures; verify via the master prior authorization process.
    CEI internal flag
    CEI internal flag presentSome entries include 'CEI = X' (example: J1559/J1561 entries show CEI fields); CEI is an internal code/flag used in the listing.
    Policy-level meaning not in excerptThe document includes CEI annotations but the precise policy definition or operational meaning is defined elsewhere in the full policy.
    Reference useCEI should be referenced when consulting the full policy for program-specific handling or documentation requirements.
    SAD / BOTH shorthand flags
    SAD*#I / SAD** / BOTH*** shorthand flags presentEntries include shorthand flags such as 'SAD*#I', 'SAD**', and 'BOTH***' next to drug lines (examples in immune globulin and other listings).
    Definitions located elsewherePrecise definitions of these shorthand flags are not provided in this excerpt and are documented in other sections of the full policy.
    Implication for coverageThese flags indicate categorizations (e.g., self-administered vs provider-administered) that affect benefit handling; check defined meanings in the master definitions section.
    Internal annotation flags (overview)
    Internal annotation flags present but not defined hereListing contains multiple internal annotations (SAD, PADP, CEL, CEI, etc.) shown alongside code entries; the excerpt does not define their exact meanings.
    Examples of annotationsEntries display PADP = X, CEI = X, SAD**L, BOTH*** in many lines across HCPCS/J/Q-code groups.
    ActionRefer to the policy's definitions section for authoritative meanings before applying program rules based on these flags.
    PADP (program) definition
    PADP = Pharmacy/Administration Drug Program (document usage)The document uses 'PADP' as a program/managed list marker (PADP-managed drugs appear across J-, Q-, and other code groups).
    Examples in listingMultiple entries (e.g., J3590 group, Q5111, J9021) show PADP fields indicating administrative tracking.
    ImplicationPADP-marked drugs are managed under the payer's specialty/drug program and typically require prior authorization via the identified channel.
    PADP flag presence
    PADP flag frequently shown in listing entriesMany code lines include a PADP field or 'PADP = X' designation (examples across J3590, J8520/J8524, Q5130 entries).
    Appears across code familiesPADP markers are present in miscellaneous J-codes, Q-code biosimilars, and J-series new entries indicating broad program application.
    Provider implicationWhen PADP appears, consult PADP program procedures for prior authorization/management requirements before billing.
    PADP — payer-assigned drug program flag
    PADP marking used to indicate program-managed drugsThe listing shows PADP or PADP = X next to many drugs, indicating payer-assigned program/managed mapping for those entries.
    Cross-reference across code typesPADP appears on C-, J-, and Q-code lines, demonstrating it is a document-level program marker rather than limited to one code family.
    Verify program rulesProviders should confirm PADP program enrollment or prior authorization requirements for PADP-marked items via the payer's authorization channels.
    J9999 / Q‑code placeholders
    J9999 and Q-codes used as placeholdersThe document includes J9999 and multiple Q-code placeholders (e.g., J9999 entries and Q2041–Q2057 listings) used for unclassified/new specialty products until a permanent HCPCS is assigned.
    ExamplesJ9999 entries list AMTAGVI, AUCATZYL and other newly added specialty products; Q2041–Q2057 denote cell and gene therapy Q-codes (YESCARTA, KYMRIAH, etc.).
    Billing noteUse the placeholder codes only per payer instructions and map to permanent HCPCS when assigned to avoid miscoding.
    PADP / CEL / SAD flags
    PADP / CEL / SAD flags in entriesEntries routinely include PADP, CEL, and SAD annotations (e.g., Q5111 SAD/BOTH***; J1561 SAD/BOTH***; many J- and Q- series lines).
    Document-level flagsThese flags indicate program participation, clinical flags, or self-administration status that affect benefit handling but are not defined in this excerpt.
    Action for providersReview the full policy definitions to interpret PADP/CEL/SAD flags for authorization and billing decisions.
    Self‑administered (SAD) note
    Self-administered (SAD) coverage noteDocument states: 'self-administered drug coverage has limited benefits through the medical benefit.'
    ImplicationDrugs marked SAD or self-administered may have limited or differing coverage under the medical benefit and may instead be managed under pharmacy benefits.
    Provider actionVerify member benefits and whether a drug marked as self-administered is covered under the medical benefit prior to administration.